Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

By driving life forward and leading the science that results in breakthrough therapies, Boehringer Ingelheim stays true to its purpose of improving the health of communities today, and for future ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well ... But also importantly, the quality of life. Because as we hopefully as an industry and through ...

Our focus is to spread awareness so patients can have more hope and higher chances for a better quality of life," said Dr. Greta Cortez, head of Medicine for Boehringer Ingelheim (Philippines) Inc.

The heritage of Boehringer Ingelheim in developing medicines for ... symptoms in order to maintain and improve patient quality of life and reduce the risk of experiencing exacerbations.

BERLIN, Oct. 15, 2024 /PRNewswire/ -- Boehringer Ingelheim ... truly look forward to our collaboration with the WHO Foundation and its partners as we want to increase access to life-saving ...